298 related articles for article (PubMed ID: 36422787)
21. Safety and efficacy of pralsetinib in RET fusion-positive non-small-cell lung cancer including as first-line therapy: update from the ARROW trial.
Griesinger F; Curigliano G; Thomas M; Subbiah V; Baik CS; Tan DSW; Lee DH; Misch D; Garralda E; Kim DW; van der Wekken AJ; Gainor JF; Paz-Ares L; Liu SV; Kalemkerian GP; Houvras Y; Bowles DW; Mansfield AS; Lin JJ; Smoljanovic V; Rahman A; Kong S; Zalutskaya A; Louie-Gao M; Boral AL; Mazières J
Ann Oncol; 2022 Nov; 33(11):1168-1178. PubMed ID: 35973665
[TBL] [Abstract][Full Text] [Related]
22. Selpercatinib monotherapy in a Chinese patient with RET fusion/ EGFR co-mutated nonsmall cell lung cancer from the Phase II LIBRETTO-321 study: a case report.
Wu L; Cheng Y; Huang D; Sun Y; Zhou C; Zhou J; Guo Y; Shao J; Zhang W; Lu S
Anticancer Drugs; 2023 Oct; 34(9):1058-1064. PubMed ID: 37265026
[TBL] [Abstract][Full Text] [Related]
23. Efficacy and safety of selpercatinib in Chinese patients with advanced
Lu S; Cheng Y; Huang D; Sun Y; Wu L; Zhou C; Guo Y; Shao J; Zhang W; Zhou J
Ther Adv Med Oncol; 2022; 14():17588359221105020. PubMed ID: 35923928
[TBL] [Abstract][Full Text] [Related]
24. The budget impact of adding pralsetinib to a US health plan formulary for treatment of non-small cell lung cancer and thyroid cancer with
Duff S; Bargiacchi F; Norregaard C; Brener M; Sullivan E
J Manag Care Spec Pharm; 2022 Feb; 28(2):218-231. PubMed ID: 34726500
[No Abstract] [Full Text] [Related]
25. Clinical evidence and adverse event management update of patients with RET- rearranged advanced non-small-cell lung cancer (NSCLC) treated with pralsetinib.
Russo GL; Bironzo P; Bennati C; Bonanno L; Catino A; Metro G; Petrini I; Russano M; Passaro A
Crit Rev Oncol Hematol; 2024 Feb; 194():104243. PubMed ID: 38135019
[TBL] [Abstract][Full Text] [Related]
26. Efficacy and safety of pralsetinib in patients with advanced RET fusion-positive non-small cell lung cancer.
Zhou Q; Zhao J; Chang J; Wang H; Fan Y; Wang K; Wu G; Nian W; Sun Y; Sun M; Wang X; Shi H; Zheng X; Yao S; Qin M; Shen Z; Yang J; Wu YL
Cancer; 2023 Oct; 129(20):3239-3251. PubMed ID: 37282666
[TBL] [Abstract][Full Text] [Related]
27. First-Line Selpercatinib or Chemotherapy and Pembrolizumab in
Zhou C; Solomon B; Loong HH; Park K; Pérol M; Arriola E; Novello S; Han B; Zhou J; Ardizzoni A; Mak MP; Santini FC; Elamin YY; Drilon A; Wolf J; Payakachat N; Uh MK; Rajakumar D; Han H; Puri T; Soldatenkova V; Lin AB; Lin BK; Goto K;
N Engl J Med; 2023 Nov; 389(20):1839-1850. PubMed ID: 37870973
[TBL] [Abstract][Full Text] [Related]
28. Intracranial Activity of Selpercatinib in Chinese Patients With Advanced
Cheng Y; Huang D; Zhou J; Zhou C; Sun Y; Wu L; Guo Y; Jingxin S; Zhang W; Lu S
JCO Precis Oncol; 2023 Jun; 7():e2200708. PubMed ID: 37315261
[TBL] [Abstract][Full Text] [Related]
29. RET Fusion-Positive Non-small Cell Lung Cancer: The Evolving Treatment Landscape.
Novello S; Califano R; Reinmuth N; Tamma A; Puri T
Oncologist; 2023 May; 28(5):402-413. PubMed ID: 36821595
[TBL] [Abstract][Full Text] [Related]
30. External control cohorts for the single-arm LIBRETTO-001 trial of selpercatinib in RET+ non-small-cell lung cancer.
Rolfo C; Hess LM; Jen MH; Peterson P; Li X; Liu H; Lai Y; Sugihara T; Kiiskinen U; Vickers A; Summers Y
ESMO Open; 2022 Aug; 7(4):100551. PubMed ID: 35930972
[TBL] [Abstract][Full Text] [Related]
31. Case report: First evidence of impressive efficacy of modulated dose selpercatinib in a young Caucasian with ANK3-RET fusion-positive NSCLC.
De Carlo E; Bertoli E; Schiappacassi M; Stanzione B; Del Conte A; Doliana R; Spina M; Bearz A
Front Oncol; 2024; 14():1307458. PubMed ID: 38420011
[TBL] [Abstract][Full Text] [Related]
32. RET rearrangements in non-small cell lung cancer: Evolving treatment landscape and future challenges.
Servetto A; Esposito D; Ferrara R; Signorelli D; Belli S; Napolitano F; Santaniello A; Ciciola P; Formisano L; Bianco R
Biochim Biophys Acta Rev Cancer; 2022 Nov; 1877(6):188810. PubMed ID: 36202311
[TBL] [Abstract][Full Text] [Related]
33. Phase III study of selpercatinib versus chemotherapy ± pembrolizumab in untreated
Solomon BJ; Zhou CC; Drilon A; Park K; Wolf J; Elamin Y; Davis HM; Soldatenkova V; Sashegyi A; Lin AB; Lin BK; F Loong HH; Novello S; Arriola E; Pérol M; Goto K; Santini FC
Future Oncol; 2021 Mar; 17(7):763-773. PubMed ID: 33150799
[TBL] [Abstract][Full Text] [Related]
34. Immune checkpoint inhibitors for RET fusion non-small cell lung cancer: hopes and challenges.
Zhao L; Zhang J; Wang N; Zhang D; Wang Z; Yu Y; Mei Q; Liao D; Jia Y; Kong F
Anticancer Drugs; 2023 Oct; 34(9):979-984. PubMed ID: 36729098
[TBL] [Abstract][Full Text] [Related]
35. Cabozantinib in patients with advanced RET-rearranged non-small-cell lung cancer: an open-label, single-centre, phase 2, single-arm trial.
Drilon A; Rekhtman N; Arcila M; Wang L; Ni A; Albano M; Van Voorthuysen M; Somwar R; Smith RS; Montecalvo J; Plodkowski A; Ginsberg MS; Riely GJ; Rudin CM; Ladanyi M; Kris MG
Lancet Oncol; 2016 Dec; 17(12):1653-1660. PubMed ID: 27825636
[TBL] [Abstract][Full Text] [Related]
36. [Chinese expert consensus on the diagnosis and treatment of advanced RET fusion-positive non-small cell lung cancer (2023 edition)].
; ;
Zhonghua Zhong Liu Za Zhi; 2023 Dec; 45(12):991-1002. PubMed ID: 38110308
[TBL] [Abstract][Full Text] [Related]
37. Pralsetinib in RET fusion-positive non-small-cell lung cancer: A real-world data (RWD) analysis from the Italian expanded access program (EAP).
Passaro A; Russo GL; Passiglia F; D'Arcangelo M; Sbrana A; Russano M; Bonanno L; Giusti R; Metro G; Bertolini F; Grisanti S; Carta A; Cecere F; Montrone M; Massa G; Perrone F; Simionato F; Guaitoli G; Scotti V; Genova C; Lugini A; Bonomi L; Attili I; de Marinis F
Lung Cancer; 2022 Dec; 174():118-124. PubMed ID: 36379124
[TBL] [Abstract][Full Text] [Related]
38. Structural basis of acquired resistance to selpercatinib and pralsetinib mediated by non-gatekeeper RET mutations.
Subbiah V; Shen T; Terzyan SS; Liu X; Hu X; Patel KP; Hu M; Cabanillas M; Behrang A; Meric-Bernstam F; Vo PTT; Mooers BHM; Wu J
Ann Oncol; 2021 Feb; 32(2):261-268. PubMed ID: 33161056
[TBL] [Abstract][Full Text] [Related]
39. Central Nervous System Disease in Patients With RET Fusion-Positive NSCLC Treated With Selpercatinib.
Murciano-Goroff YR; Falcon CJ; Lin ST; Chacko C; Grimaldi G; Liu D; Wilhelm C; Iasonos A; Drilon A
J Thorac Oncol; 2023 May; 18(5):620-627. PubMed ID: 36657661
[TBL] [Abstract][Full Text] [Related]
40. FDA Approval Summary: Selpercatinib for the Treatment of Advanced RET Fusion-Positive Solid Tumors.
Duke ES; Bradford D; Marcovitz M; Amatya AK; Mishra-Kalyani PS; Nguyen E; Price LSL; Fourie Zirkelbach J; Li Y; Bi Y; Kraft J; Dorff SE; Scepura B; Stephenson M; Ojofeitimi I; Nair A; Han Y; Tezak Z; Lemery SJ; Pazdur R; Larkins E; Singh H
Clin Cancer Res; 2023 Sep; 29(18):3573-3578. PubMed ID: 37265412
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
